News > RMMS Wins Summary Judgment of Non-Infringement for Generic Client in Patent Dispute Involving Pfizer's Blockbuster Prescription Drug Neurontin®

RMMS Wins Summary Judgment of Non-Infringement for Generic Client in Patent Dispute Involving Pfizer's Blockbuster Prescription Drug Neurontin®

08/22/2005

On August 22, 2005, the U.S. District Court for the District of New Jersey issued two 30-page decisions granting summary judgment on non-infringement for RMMS's generic client, Apotex, on Pfizer's U.S. Patent No. 6,054,482 for Neurontin®, a prescription drug approved to treat seizure and postherpetic neuralgia. In the long-running patent dispute dating back to 1998, RMMS attorneys have successfully obtained judgments for Apotex on all 3 of Pfizer's Neurontin® patents.